BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with AchondroplasiaGlobeNewsWire • 12/13/23
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 12/05/23
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)GlobeNewsWire • 11/12/23
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023GlobeNewsWire • 11/09/23
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 11/02/23
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/26/23
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/11/23
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)GlobeNewsWire • 10/10/23
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)GlobeNewsWire • 10/09/23
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy TreatmentsBusiness Wire • 10/03/23
BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fundMarket Watch • 09/25/23
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/07/23
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with AchondroplasiaGlobeNewsWire • 09/06/23
Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.Investors Business Daily • 08/28/23
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023GlobeNewsWire • 08/27/23
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023GlobeNewsWire • 08/24/23
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/23
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 08/03/23
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 StudyGlobeNewsWire • 07/31/23